New and Established Investigator Research Grant Program
How to Apply
|Grant Instructions and Application|
SUBMITTING YOUR APPLICATION
APPLICATION DEADLINE: September 30, 2021, by 5 p.m. Eastern Time.
Applications should be submitted by one of the following methods:
- Types of Grants
- Appropriate Areas of Research and Criteria
- Review Considerations
- Review Criteria
- Award Criteria
- Progress, Financial Reports and Carry-Over Requests
Effective for the 2022 grant funding cycle, the Scleroderma Foundation has increase its peer-reviewed scientific research funding to $2.723 million annually, more than doubling its commitment. The Foundation is also increasing the amount of its awards by $50,000 per grant to $200,000.
To accommodate the change in funding opportunities, the 2021 proposal submission deadline has been extended from the traditional date of September 15 to the 30th of September.Grant applications must be received in the Foundation's national office on that date by 5 p.m. Eastern Time. Postmark dates do not meet the requirement.
The funding increase includes specific requests for proposals in two key areas: scleroderma-related lung disease research and pediatric scleroderma. A specific, donor-funded grant of $200,000 will be awarded to an established investigator conducting scleroderma-related lung disease research. Pediatric-scleroderma research is earmarked for up to $500,000 in awards and is open to submissions from new and established investigators.
Applicants for the scleroderma-related lung research grant should select "Established Investigator Grant" when completing the application. Applicants for pediatric scleroderma research grant may select either "New" or "Established Investigator" categories.
Researchers interested in the grant program can find more information by reviewing Types of Grants offered, Appropriate Areas of Research and Criteria, and the Grant Application and Instructions.
Appropriate research areas may include but are not limited to the following as they relate to scleroderma:
- Scleroderma-related lung disease.
- Pediatric scleroderma.
- Vascular manifestations.
- Studies of animal models.
- Therapeutic modalities.
- Mechanisms of end organ damage.
- Immunologic studies.
- Endothelial cell biology.
- Fibroblast biology.
- Models and markers of gender and genetic factors.
- Cell signaling.
- Epidemiology studies.
- Matrix biology.
- Stem cell biology.
- Health services research (e.g. quality of life, health care delivery.)
- Study of clinical manifestation.
- Applicants may submit only one grant application per grant review.
- No more than two (2) grants in any given year will be awarded to any institution or major branches of institution (e.g. University of California San Diego, University of California San Francisco.)
- Unless unusual circumstances prevail, Scleroderma Foundation may fund applicants for only three consecutive years for New Investigator Grants and two years for Established Investigator Grants.
- Applications failing to strictly adhere to the Scleroderma Foundation guidelines will be administratively disqualified and not be further reviewed.
- Applicants may hold only one grant at any given time from the Scleroderma Foundation.
- Applicants who have been funded by the Scleroderma Foundation must wait one year after their grant has ended to reapply.
- Revised grants utilizing critiques from the previous submission may be resubmitted no more than once.
- Before research can begin, grant agreements must be signed and all approvals such as IRB must be obtained.
The Scleroderma Foundation peer review committee will review applications for responsiveness to the research objectives of the Scleroderma Foundation and for the eligibility of the Principal Investigator under the requirements stated above. Applications found to be unresponsive to these guidelines will be returned without further consideration. Applications that are complete and responsive to the guidelines of the Scleroderma Foundation will be evaluated for scientific and technical merit.
In the written review, comments on the following aspects of the application will be made in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in the assignment of the overall score.
- Significance. Does this study address an important problem related to SSc? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field?
- Approach. Are the conceptual framework design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the investigator acknowledge potential problem areas and consider alternative tactics?
- Innovation. Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- Investigator. Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? Is there evidence the applicant is committed to pursuing research related to scleroderma?
- Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
The personnel category will be reviewed for appropriate staffing based on the requested percent effort. The direct costs budget request will be reviewed for consistency with the proposed methods and specific aims. Budgetary adjustments may be made by the review panel or the Scleroderma Foundation. The duration of support will be reviewed to determine if it is appropriate to ensure successful completion of the requested scope of the project.
The following will be considered in making funding decisions:
- Scientific merit of the proposed project as determined by peer review.
- Importance of the area to scleroderma research.
- Availability of funds.
Progress and financial reports are required at each grant award year, and as requested by the Scleroderma Foundation. Further details of what is required is included in the grant agreement. All required forms are available on the website.
An additional and final report will be due 90 days after the completion of the grant, describing any publications and subsequent funding.
Failure to meet reporting requirements may result in future ineligibility to apply to the Foundation's research program for the primary investigator, key personnel, and other investigators at the institution.
Carry forward requests exceeding 5% of the annual grant award must be submitted with a justification, progress, and financial report for further review by the Scleroderma Foundation. Requests may not exceed 20% of the annual grant award amount and may not exceed six months.
If you are a current grantee, download reporting forms here.